AstraZeneca’s Voydeya granted first-ever regulatory approval

Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It is indicated in Japan in combination with C5 inhibitor therapy when patients have had an insufficient response to such C5 inhibitors.

Developed by Alexion Pharmaceuticals, danicopan was picked up by UK pharma major AstraZeneca (LSE: AZN) through its  $39 billion acquisition of the rare disease specialist.

Voydeya is a first-in-class, oral, Factor D inhibitor developed as add-on to proven standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) – which AstraZeneca also acquired with its buy of Alexion - to address the needs of the subset of patients (around 10-20%) with PNH who experience clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitor.